Pyxis Oncology, Inc. (NASDAQ:PYXS) CFO Pamela Ann Connealy Buys 88,850 Shares

Pyxis Oncology, Inc. (NASDAQ:PYXS) CFO Pamela Ann Connealy acquired 88,850 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were bought at an average price of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the purchase, the chief financial officer now owns 1,199,143 shares in the company, valued at approximately $2,350,320.28. This represents a 8.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Pyxis Oncology Trading Up 3.4 %

PYXS opened at $1.83 on Friday. The firm has a 50-day moving average price of $3.50 and a 200-day moving average price of $3.55. Pyxis Oncology, Inc. has a twelve month low of $1.48 and a twelve month high of $6.85.

Institutional Investors Weigh In On Pyxis Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of PYXS. Barclays PLC boosted its holdings in shares of Pyxis Oncology by 275.0% in the third quarter. Barclays PLC now owns 64,089 shares of the company’s stock worth $235,000 after acquiring an additional 46,997 shares during the period. Geode Capital Management LLC boosted its stake in Pyxis Oncology by 5.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after purchasing an additional 57,016 shares during the period. Public Employees Retirement System of Ohio purchased a new position in Pyxis Oncology during the 3rd quarter valued at about $107,000. XTX Topco Ltd increased its position in shares of Pyxis Oncology by 133.6% during the third quarter. XTX Topco Ltd now owns 84,771 shares of the company’s stock valued at $311,000 after buying an additional 48,481 shares during the period. Finally, Jane Street Group LLC lifted its holdings in shares of Pyxis Oncology by 40.8% in the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after buying an additional 14,349 shares in the last quarter. Institutional investors own 39.09% of the company’s stock.

Analyst Ratings Changes

PYXS has been the subject of several analyst reports. Royal Bank of Canada increased their price objective on shares of Pyxis Oncology from $7.00 to $10.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. William Blair cut Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Stephens began coverage on Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective for the company. Stifel Nicolaus started coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.